These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24535076)

  • 1. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
    Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
    Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
    Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
    Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer.
    Awad S; Tan BH; Cui H; Bhalla A; Fearon KC; Parsons SL; Catton JA; Lobo DN
    Clin Nutr; 2012 Feb; 31(1):74-7. PubMed ID: 21875767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
    Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
    den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
    BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
    Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
    Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
    Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
    Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
    Cooper AB; Slack R; Fogelman D; Holmes HM; Petzel M; Parker N; Balachandran A; Garg N; Ngo-Huang A; Varadhachary G; Evans DB; Lee JE; Aloia T; Conrad C; Vauthey JN; Fleming JB; Katz MH
    Ann Surg Oncol; 2015 Jul; 22(7):2416-23. PubMed ID: 25519927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
    Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
    Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.
    Guinan EM; Doyle SL; Bennett AE; O'Neill L; Gannon J; Elliott JA; O'Sullivan J; Reynolds JV; Hussey J
    Support Care Cancer; 2018 May; 26(5):1569-1576. PubMed ID: 29197960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment.
    Hagens ERC; Feenstra ML; van Egmond MA; van Laarhoven HWM; Hulshof MCCM; Boshier PR; Low DE; van Berge Henegouwen MI; Gisbertz SS
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):756-767. PubMed ID: 32096923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.
    Tamandl D; Paireder M; Asari R; Baltzer PA; Schoppmann SF; Ba-Ssalamah A
    Eur Radiol; 2016 May; 26(5):1359-67. PubMed ID: 26334504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.